Premium
An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome
Author(s) -
Hollander Peter,
Rostgaard Klaus,
Smedby Karin E.,
Molin Daniel,
Loskog Angelica,
de Nully Brown Peter,
Enblad Gunilla,
Amini RoseMarie,
Hjalgrim Henrik,
Glimelius Ingrid
Publication year - 2018
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12987
Subject(s) - lymphoma , immune system , signature (topology) , medicine , outcome (game theory) , immunology , tumor microenvironment , geometry , mathematics , mathematical economics
Objective The classical Hodgkin lymphoma ( cHL ) tumor microenvironment shows an ongoing inflammatory response consisting of varying degrees of infiltrating eosinophils, mast cells, macrophages, regulatory T lymphocytes (Tregs), and activated lymphocytes surrounding the malignant cells. Herein, different immune signatures are characterized and correlated with treatment outcome. Methods Tumor‐infiltrating leukocytes were phenotyped in biopsies from 459 patients with cHL . Time to progression ( TTP ) (primary progression, relapse, or death from cHL ) and overall survival were analyzed using Cox proportional hazards regression. Results The leukocyte infiltration in the microenvironment was highly diverse between patients and was categorized in 4 immune signatures (active, anergic, innate, or mixed). A high proportion of Tregs (anergic) resulted in shorter TTP (median 12.9‐year follow‐up) in age‐adjusted analyses (hazard ratio = 1.82; 95% confidence interval 1.05‐3‐15). Epstein‐Barr virus ( EBV )‐positive cases had higher proportions of macrophages and activated lymphocytes than EBV negative, but neither of those leukocytes predicted prognosis. Conclusions Abundant Tregs (anergic signature) indicate a shorter TTP , particularly in younger patients. This is probably due to a reduced ability of the immune system to attack the tumor cells. Our data warrant further investigation if these suggested immune signatures could predict outcome of immunotherapy such as immune checkpoint inhibitors.